Abstract

Simple SummaryCD81 is highly expressed in glioblastoma (GBM) as a transmembrane protein. The functional study demonstrated that CD81 contributed to radioresistance of GBM. Further evidence showed that CD81 expression was closely related to DNA damage response and homologous recombination repair (HRR) was responsible for the CD81 mediated radioresistance. Particularly, nuclear membrane protein CD81 assisted the nuclear transport of Rad51, a key protein involved in HRR process after irradiation. Overall, CD81 may be utility as a predictive biomarker and therapeutic target of radioresistant GBM.Glioblastoma (GBM) is the most common type of primary tumor in central nervous system in adult with a 5-year survival rate of ≤5%. Despite of recent advances in tumor radiotherapy, the prognosis of GBM remains to be dismal due to radioresistance. In this study, we identified CD81 as a potential biomarker of GBM radioresistance with the analysis of upregulated genes in human glioma radioresistant cell lines U251R and T98G in comparison with U251 cells. In vitro and in vivo experiments demonstrated that suppressing CD81 by siRNA/shRNA enhanced radiation-induced cell killing and DNA damage of γ-H2AX formation, and delayed tumor xenograft growth of GBM. Mechanistically, we found that knockdown of CD81 significantly decreased radiation-induced expression of nuclear Rad51, a key protein involved in homologous recombination repair (HRR) of DNA, suggesting that CD81 is essential for DNA damage response. Meanwhile, when the cells were treated with B02, a Rad51 inhibitor, silencing CD81 would not sensitize GBM cells to radiation, which further illustrates that Rad51 acts as an effector protein of CD81 in tumor radioresistance. Dual immunofluorescence staining of CD81 and Rad51 illustrated that nuclear membrane CD81 contributed to the nuclear transport of Rad51 after irradiation. In conclusion, we demonstrated for the first time that CD81 not only played a vital role in DNA repair through regulating Rad51 nuclear transport, but also might serve as a potential target of GBM radiotherapy.

Highlights

  • Glioblastoma (GBM) is the most common lethal brain cancer and has been classified into the grade IV glioma with extremely high malignancy by WHO [1]

  • To know much more genes precisely involved in the radioresistance of GBM, here we further explored the differential expression genes (DEGs) between U251 and T98G cells by Tandem Mass Tag (TMT) analysis

  • T98G is a kind of glioblastoma multiforme cells and had a radioresistance much higher than U251R and U251 cells (Figure 1A)

Read more

Summary

Introduction

Glioblastoma (GBM) is the most common lethal brain cancer and has been classified into the grade IV glioma with extremely high malignancy by WHO [1]. Despite of the multimodality therapy, the life expectancy for GBM patients remains extremely poor with a median survival of 14.6 months [3,4]. In order to identify novel biomarker of GBM radioresistance, we performed Tandem Mass Tag (TMT) analysis on three GBM cell lines and screened out a list of differential expression genes (DEGs) with a variety of functions in radioresistance. Analysis of these DEGs using public clinical databases revealed for the first time that CD81 could be a novel regulator of radioresistance. As a molecule located on various membrane structures, it is of great concern how CD81 promotes resistance to ionizing radiation

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call